Product Overview
[Drug Name]
Generic Name: Thymosin Enteric-Coated Tablets
Trade Name: Oberna Thymosin Enteric-Coated Tablets 20mg x 12 Tablets
[Main Ingredients]
The main ingredient of this product is thymosin, a biologically active polypeptide extracted from the thymus of healthy calves.
[Properties]
This product is an enteric-coated tablet. After removing the coating, it appears off-white or pale yellow to yellow-brown.
[Indications/Main Functions]
① For patients with chronic hepatitis B aged 18 years and above, who experience decreased cellular immunity due to thymus atrophy after age 18; ② For various primary or secondary T-cell deficiency diseases; ③ For certain autoimmune diseases (such as rheumatoid arthritis and systemic lupus erythematosus); ④ For various diseases with impaired cellular immunity; ② For adjunctive treatment of tumors.
[Specifications]
20mg x 12 tablets
[Dosage and Administration]
Oral administration. 20mg (one tablet) 1-3 times daily, or as directed by a physician.
[Adverse Reactions]
1. Well tolerated. Some patients may experience adverse reactions such as nausea, fever, dizziness, chest tightness, and weakness. A few patients may experience occasional drowsiness. 2. Patients with chronic hepatitis B may experience a transient increase in ALT levels when using this product. If there are no signs of liver failure, this product can continue to be used.
[Contraindications]
This product is contraindicated in patients with allergic reactions or those undergoing organ transplants.
[Drug Interactions]
1. This product can be used in combination with many commonly used medications, including interferons, anti-inflammatory drugs, antibiotics, hormones, analgesics, antihypertensives, diuretics, cardiovascular medications, central nervous system medications, and contraceptives, without any interference. 2. This product has a synergistic effect with interferon in improving immune function.
[Precautions]
1. This product exerts its therapeutic effect by enhancing the patient's immune function. Therefore, it should not be used in patients receiving immunosuppressive therapy (such as organ transplant recipients) unless the benefits clearly outweigh the risks. 2. Liver function should be monitored regularly during treatment. 3. Use with caution in patients under 18 years of age.
[Pediatric Use]
The safety and efficacy of this drug have not been established in patients under 18 years of age.
[Overdose]
There have been no reports of overdose (therapeutic or accidental) in humans. Animal toxicity studies have shown no adverse reactions at doses below 10 mg/kg (the highest dose currently used).
